Essity B, SE0009922164

Essity stock faces Health & Medical growth gap at Jefferies

Published on 11/17/2026 at 10:29 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Essity stock faces a growth gap in Health & Medical as healthcare budgets tighten. Management sees North America and focused acquisitions as key opportunities.

Growth ambition meets near-term pressure

  • Essity's Health & Medical business delivered 1.6% organic growth in the first nine months, below its ambition of more than 3%.
  • Management expects healthcare budget pressure, tender timing and rising costs to weigh on the business over the next 12 months.
  • North America and targeted acquisitions remain central to the division's medium-term expansion plan.
Essity B, SE0009922164, Illustration mit AI erstellt.

Essity's Health & Medical division faces a gap between current performance and its growth ambitions, according to management comments at the Jefferies Global Healthcare Conference on Monday, November 16, 2026, reported by Investing.com. The business recorded 1.6% organic growth in the first nine months, while its ambition remains consistently above 3%.

Essity stock traded at 26.51 euros on Lang & Schwarz at 10:17 CET on Tuesday, November 17.

Healthcare demand remains structurally attractive

Health & Medical accounts for about 20% of group sales and 25% of group profit, making it a significant contributor despite its smaller revenue share. The division includes incontinence care under the TENA brand, wound care, compression therapy and soft orthopedics.

Management described the underlying markets as supported by aging populations and a rising incidence of chronic conditions. The addressable market for the division was put at about 17 billion euros, with annual market growth of 3% to 4%. Essity said it serves about 1 billion people each day across 150 markets.

Margins face a tougher operating backdrop

The division's year-to-date EBITDA margin stood at 18.6%, below the long-term target of at least 19%. Anand Chandarana, head of Essity's Health & Medical business, said cost pressures were expected to intensify over the coming quarters and the next 12 months.

Management pointed to selective pricing, product mix and productivity measures as the main levers for margin improvement. Healthcare systems are under budget pressure, while tender cycles can make quarterly performance uneven. Contracts in incontinence care often last four to five years, increasing the importance of preparation before tenders are launched.

North America and acquisitions offer upside

North America currently contributes 17% of divisional sales, a share that management considers below its ambition. Essity sees opportunities to expand in Canada through medical categories and to build on its number-three incontinence position in the United States.

Acquisitions are intended to complement, rather than replace, organic growth. Potential targets include advanced wound care, solutions that prevent or reduce incontinence, and technologies related to lymphology and compression therapy. Management said any transaction would need a strategic rationale, synergies and clear value creation.

Investment supports the Tork platform

The conference comments followed Essity's announcement of a planned investment of approximately 850 million Swedish kronor in a new tissue machine at Lilla Edet in Sweden. The announcement, published on November 16 by ISSA, said the machine is expected to start operating in the fourth quarter of 2028 and will have 50% higher capacity than the existing machine. The project is designed to support Professional Hygiene and the Tork brand.

Essity AB Class B

  • Company: Essity AB (publ)
  • ISIN: SE0009922164
  • Ticker: ESSITY-B.ST
  • Primary exchange: Nasdaq Stockholm
  • Latest Lang & Schwarz quote: 26.51 euros at 10:17 CET on November 17, 2026
  • Sector: Consumer Defensive

The broader Swedish equity market can be followed through the OMXS30 market overview.

More news and analyses on Essity stock

Disclaimer...
en | SE0009922164 | ESSITY B | boerse | 70525888 | bgmi